Table 2.
Strata, Dose levels & Dose-Limiting Toxicity (DLT) events
| Stratum 1* | ||||
|---|---|---|---|---|
| Dose Level |
Flavopiridol | Imatinib | No. of patients treated | DLT |
| 1 | 30 | 400 | 3 | |
| 2 | 30 | 600 | 3 | |
| 3 | 45 | 600 | 3 | |
| 4 | 60 | 600 | 6 | Grade 3 cholecystitis |
| Stratum 2* | ||||
| Dose Level |
Flavopiridol | Imatinib | No. of patients treated | DLT |
| 1 | 30 | 400 | 3 | |
| 2 | 30 | 600 | 0 | |
| 3 | 45 | 600 | 3 | |
*
Patients with <15% blasts in PB and BM, and no recent myelosuppressive therapy were assigned to stratum 1. Patients with ≥15% blasts in the BM or PB were assigned to stratum 2, as were patients with <15% blasts who had grade 1 or 2 neutropenia or thrombocytopenia from previous myelosuppressive therapy.